ADIPOQ and chronic obstructive pulmonary disease: Pooled effect size showed that the serum adiponectin levels were higher in COPD patients than those in controls (SMD: 1.09, 95% CI [0.73–1.45], P < 0.001; I2 = 90.8%, P < 0.001; Figure 2).